Cell therapy with autologous mesenchymal stem cells-how the disease process impacts clinical considerations

Cytotherapy. 2013 Aug;15(8):893-904. doi: 10.1016/j.jcyt.2013.01.218. Epub 2013 Jun 7.


The prospective clinical use of multipotent mesenchymal stromal cells (MSCs) holds enormous promise for the treatment of a large number of degenerative and age-related diseases. In particular, autologous MSCs isolated from bone marrow (BM) are considered safe and have been extensively evaluated in clinical trials. Nevertheless, different efficacies have been reported, depending on the health status and age of the donor. In addition, the biological functions of BM-MSCs from patients with various diseases may be impaired. Furthermore, medical treatments such as long-term chemotherapy and immunomodulatory therapy may damage the BM microenvironment and affect the therapeutic potential of MSCs. Therefore, a number of practical problems must be addressed before autologous BM-MSCs can be widely applied with higher efficiency in patients. As such, this review focuses on various factors that directly influence the biological properties of BM-MSCs, and we discuss the possible mechanisms of these alterations.

Keywords: bone marrow; cell therapy; hematopoietic stem cell; mesenchymal stromal cell.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Autoimmune Diseases / therapy*
  • Bone Marrow Cells
  • Cell Differentiation
  • Cell Proliferation
  • Cell- and Tissue-Based Therapy / methods*
  • Cellular Senescence
  • Hematologic Diseases / therapy*
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cells
  • Humans
  • Mesenchymal Stem Cell Transplantation*
  • Mesenchymal Stem Cells*
  • Metabolic Diseases / therapy*
  • Transplantation, Autologous